UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Bottom-up Meets Top-down: Complementary Physiologically Based Pharmacokinetic and Population Pharmacokinetic Modeling for Regulatory Approval of a Dosing Algorithm of Valganciclovir in Very Young Children

Clinical pharmacology and therapeutics, 2016-12, Vol.100 (6), p.761-769

2016

Volltextzugriff (PDF)

A Comprehensive Hepatitis C Viral Kinetic Model Explaining Cure

Clinical pharmacology and therapeutics, 2010-06, Vol.87 (6), p.706-713

2010

Volltextzugriff (PDF)

A novel strategy for physiologically based predictions of human pharmacokinetics

Clinical pharmacokinetics, 2006-01, Vol.45 (5), p.511-542

2006

Volltextzugriff (PDF)

Integrated pharmacokinetics and pharmacodynamics of the novel catechol‐O‐methyltransferase inhibitor tolcapone during first administration to humans

Clinical pharmacology and therapeutics, 1995-05, Vol.57 (5), p.508-517

1995

Volltextzugriff (PDF)

Pharmacokinetics of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Locally Advanced or Metastatic Solid Tumors: the Role of Alpha-1-Acid Glycoprotein Binding

Clinical cancer research, 2011-04, Vol.17 (8), p.2512-2520

2011

Volltextzugriff (PDF)

Pharmacokinetic‐pharmacodynamic interaction between the COMT inhibitor tolcapone and single‐dose levodopa

British journal of clinical pharmacology, 1995-09, Vol.40 (3), p.253-262

1995

Volltextzugriff (PDF)

The effect of tolcapone on levodopa pharmacokinetics is independent of levodopa/carbidopa formulation

Journal of neurology, 1998-04, Vol.245 (4), p.223-230

1998

Volltextzugriff (PDF)

Pharmacokinetics and pharmacodynamics after oral and intravenous administration of tolcapone, a novel adjunct to Parkinson's disease therapy

European journal of clinical pharmacology, 1998-07, Vol.54 (5), p.443-447

1998

Volltextzugriff (PDF)

Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderly

Clinical pharmacology and therapeutics, 1997-09, Vol.62 (3), p.300-310

1997

Volltextzugriff (PDF)

Effect of liver impairment on the pharmacokinetics of tolcapone and its metabolites

Clinical pharmacology and therapeutics, 1998-06, Vol.63 (6), p.646-654

1998

Volltextzugriff (PDF)

Effect of Tolcapone on the Haemodynamic Effects and Tolerability of Desipramine

European neurology, 2000-01, Vol.44 (2), p.94-103

2000

Volltextzugriff (PDF)

Lack of Interaction between Tolcapone and Tolbutamide in Healthy Volunteers

Journal of clinical pharmacology, 2000-05, Vol.40 (5), p.544-551

2000

Volltextzugriff (PDF)

COMT inhibition with tolcapone does not affect carbidopa pharmacokinetics in parkinsonian patients in levodopa/carbidopa (Sinemet®)

British journal of clinical pharmacology, 1999-09, Vol.48 (3), p.449-452

1999

Volltextzugriff (PDF)

Multiple-dose clinical pharmacology of the catechol-O-methyl-transferase inhibitor tolcapone in elderly subjects

European journal of clinical pharmacology, 1996, Vol.50 (1-2), p.47-55

1996

Volltextzugriff (PDF)

Effect of tolcapone on plasma levodopa concentrations after coadministration with levodopa/carbidopa to healthy volunteers

Clinical neuropharmacology, 1997-12, Vol.20 (6), p.531-541

1997

Volltextzugriff (PDF)

Saquinavir and ritonavir pharmacokinetics following combined ritonavir and saquinavir (soft gelatin capsules) administration

British journal of clinical pharmacology, 2001-09, Vol.52 (3), p.255-264

2001

Volltextzugriff (PDF)

Pharmacokinetics, pharmacodynamics, and tolerability of tolcapone: a review of early studies in volunteers

Neurology, 1998-05, Vol.50 (5 Suppl 5), p.S31

Jorga, K M

1998

Volltextzugriff (PDF)

Metabolism and excretion of tolcapone, a novel inhibitor of catechol‐O‐methyltransferase

British journal of clinical pharmacology, 1999-10, Vol.48 (4), p.513-520

1999

Volltextzugriff (PDF)

Clinical, pharmacokinetic, and pharmacodynamic effects of tolcapone withdrawal in levodopa-treated patients with parkinsonism

Clinical neuropharmacology, 2000-03, Vol.23 (2), p.98-105

2000

Volltextzugriff (PDF)

The interaction of saquinavir (soft gelatin capsule) with ketoconazole, erythromycin and rifampicin : comparison of the effect in healthy volunteers and in HIV-infected patients

European journal of clinical pharmacology, 2001-05, Vol.57 (2), p.115-121

2001

Volltextzugriff (PDF)

Response to Garrido et al.: "Side effects of the catechol-O-methyl-transferase inhibitor Ro 40-7592 in rabbits"

Clinical neuropharmacology, 1996-02, Vol.19 (1), p.98-99

1996

Volltextzugriff (PDF)

Optimal design for multivariate response pharmacokinetic models

Journal of pharmacokinetics and pharmacodynamics, 2006-04, Vol.33 (2), p.97-124

2006

Volltextzugriff (PDF)

Pharmacokinetics and pharmacodynamics of saquinavir in pediatric patients with human immunodeficiency virus infection

Clinical pharmacology and therapeutics, 2002-03, Vol.71 (3), p.122-130

2002

Volltextzugriff (PDF)

Population pharmacokinetics of levodopa in patients with Parkinson's disease treated with tolcapone

Clinical pharmacology and therapeutics, 2000-06, Vol.67 (6), p.610-620

2000

Volltextzugriff (PDF)

Population pharmacokinetics of tolcapone in parkinsonian patients in dose finding studies

British journal of clinical pharmacology, 2000-01, Vol.49 (1), p.39-48

2000

Volltextzugriff (PDF)

1 – 25 von 35

Suche als RSS-Feed

Aktive Filter

KollektionMEDLINE

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(35)
Mit Volltextzugriff
(28)

Publikationsform

Artikel
(35)

Sprache

Englisch
(35)

Erscheinungsjahr

n.n

Thema

Humans
(34)
Life Sciences & Biomedicine
(30)
Science & Technology
(30)
Male
(28)
Biological And Medical Sciences
(27)
Medical Sciences
(27)
Pharmacology. Drug Treatments
(26)
Nitrophenols
(20)
Pharmacology & Pharmacy
(20)
Adult
(19)
Female
(18)
Anticonvulsants. Antiepileptics. Antiparkinson Agents
(17)
Neuropharmacology
(17)
Middle Aged
(15)
Tolcapone
(15)
Pharmacokinetics
(13)
Benzophenones - Pharmacokinetics
(12)
Benzophenones - Pharmacology
(12)
Aged
(11)
Catechol O-Methyltransferase Inhibitors
(11)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Bottom-up Meets Top-down: Complementary Physiologically Based Pharmacokinetic and Population Pharmacokinetic Modeling for Regulatory Approval of a Dosing Algorithm of Valganciclovir in Very Young Children

A Comprehensive Hepatitis C Viral Kinetic Model Explaining Cure

A novel strategy for physiologically based predictions of human pharmacokinetics

Integrated pharmacokinetics and pharmacodynamics of the novel catechol‐O‐methyltransferase inhibitor tolcapone during first administration to humans

Pharmacokinetics of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Locally Advanced or Metastatic Solid Tumors: the Role of Alpha-1-Acid Glycoprotein Binding

Pharmacokinetic‐pharmacodynamic interaction between the COMT inhibitor tolcapone and single‐dose levodopa

The effect of tolcapone on levodopa pharmacokinetics is independent of levodopa/carbidopa formulation

Pharmacokinetics and pharmacodynamics after oral and intravenous administration of tolcapone, a novel adjunct to Parkinson's disease therapy

Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderly

Effect of liver impairment on the pharmacokinetics of tolcapone and its metabolites

Effect of Tolcapone on the Haemodynamic Effects and Tolerability of Desipramine

Lack of Interaction between Tolcapone and Tolbutamide in Healthy Volunteers

COMT inhibition with tolcapone does not affect carbidopa pharmacokinetics in parkinsonian patients in levodopa/carbidopa (Sinemet®)

Multiple-dose clinical pharmacology of the catechol-O-methyl-transferase inhibitor tolcapone in elderly subjects

Effect of tolcapone on plasma levodopa concentrations after coadministration with levodopa/carbidopa to healthy volunteers

Saquinavir and ritonavir pharmacokinetics following combined ritonavir and saquinavir (soft gelatin capsules) administration

Pharmacokinetics, pharmacodynamics, and tolerability of tolcapone: a review of early studies in volunteers

Metabolism and excretion of tolcapone, a novel inhibitor of catechol‐O‐methyltransferase

Clinical, pharmacokinetic, and pharmacodynamic effects of tolcapone withdrawal in levodopa-treated patients with parkinsonism

The interaction of saquinavir (soft gelatin capsule) with ketoconazole, erythromycin and rifampicin : comparison of the effect in healthy volunteers and in HIV-infected patients

Response to Garrido et al.: "Side effects of the catechol-O-methyl-transferase inhibitor Ro 40-7592 in rabbits"

Optimal design for multivariate response pharmacokinetic models

Pharmacokinetics and pharmacodynamics of saquinavir in pediatric patients with human immunodeficiency virus infection

Population pharmacokinetics of levodopa in patients with Parkinson's disease treated with tolcapone

Population pharmacokinetics of tolcapone in parkinsonian patients in dose finding studies

Aktive Filter

Suchergebnisse filtern